MarketVIEW Adolescent & STD Vaccines  ·  April 2019 edition

HPV Therapeutic
Vaccines Forecast

Prophylactic HPV vaccination is now real-world proof against future cervical cancer, but it does nothing for the hundreds of millions already infected or already living with HPV-driven neoplasia or cancer. This is the independent, patient-based commercial assessment of the therapeutic HPV vaccine opportunity for major Western markets, updated for a pipeline in which both historic frontrunners have been discontinued and a new field leader, PDS Biotech's PDS0101, has emerged in registrational testing.

AXAL & US VGX-3100 Both Discontinued PDS0101 Now in Phase 3 (Head & Neck) Major Western Markets to 2035 662,301 New Cervical Cancers a Year
Product catalogue
VAMV050
April 2019 edition

Format
Executive presentation (185 slides) + Excel model (optional)
Coverage
Major Western markets
Indications
HPV16/18+ CIN/AIN/PIN/VIN/VAIN & established cancers
Forecast horizon
To 2035
Approach
Patient-based value/volume forecast
Base edition
April 2019
Availability
Syndicated / bespoke
662,301
New cervical cancer cases
worldwide a year (GLOBOCAN 2022)
348,874
Cervical cancer deaths
worldwide a year (GLOBOCAN 2022)
11-12%
Estimated worldwide HPV
prevalence among adults
4
Active clinical-stage HPV
therapeutic vaccine candidates
Disease background

Why a therapeutic vaccine is still needed, even as prevention works

Human papillomavirus is one of the most common infections in humanity, and its highest-risk types remain the world's leading infectious cause of cancer. Understanding why prophylactic vaccination cannot help those already infected, and how the field's competitive landscape has been reshaped since this report's original 2019 edition, is central to understanding what a workable therapeutic vaccine could still be worth.

GLOBOCAN 2022, WHO/IARC & 2025/26 pipeline data

Pathogen overview - Human papillomavirus (HPV)

Human papillomaviruses, members of the papillomaviridae family, are extremely common, with an estimated worldwide prevalence of around 11 to 12% among sexually active adults. Although nearly all sexually active men and women acquire the virus at some point in their lives, most infections are asymptomatic and self-limiting, with roughly 90% clearing within two years. High-risk genotypes, chiefly HPV16 and HPV18, can instead persist and drive dysplasia in the cells lining the mouth, throat or anogenital tract, including the cervix, and that dysplasia can progress through defined neoplastic grades (such as CIN2/3, AIN, PIN, VIN and VAIN) toward invasive cancer.

The scale of that progression is now better quantified than at any point in this report's history. GLOBOCAN 2022 estimates 662,301 new cervical cancer cases and 348,874 deaths worldwide each year, making it the fourth most common cancer in women globally, with more than 85% of cases and 90% of deaths concentrated in women aged 40 and over and a marked concentration of burden in lower-income regions. On unchanged trends, GLOBOCAN projects this rising further, to 760,082 cases and 411,035 deaths a year by 2030. Beyond the cervix, HPV16/18 are also responsible for a substantial share of oropharyngeal and anal cancers, together with smaller contributions to vulvar, vaginal and penile cancer, taking the total HPV-attributable cancer burden to roughly 630,000 to 690,000 cases a year worldwide by most WHO/IARC-derived estimates.

Crucially, in most HPV-associated malignancies the virus has already achieved genomic integration into the host cell genome by the time disease is detected. This is the central reason a prophylactic vaccine, however effective at preventing new infection, cannot treat existing dysplasia or cancer: it primes neutralising antibodies against the viral capsid before exposure, but does nothing to clear a persistent infection or an already-transformed cell population. A therapeutic vaccine instead needs to elicit a cell-mediated immune response, typically targeting the viral oncoproteins E6 and E7 that drive and sustain malignant transformation, capable of recognising and destroying already-infected or already-transformed cells. That distinct mechanism of action, not a simple extension of prophylactic technology, is what the therapeutic HPV vaccine field has spent more than two decades trying to deliver.

Twenty years on from the first mass rollout of prophylactic HPV vaccination, real-world evidence of impact is now substantial, and it sharpens rather than removes the case for a therapeutic option. In England, the Falcaro et al. analyses found cervical cancer incidence reduced by 87% among women offered the bivalent vaccine at age 12-13 relative to unvaccinated cohorts, with CIN3 incidence down 97% in the same group; a mortality follow-up to the end of 2024 attributed around 200 fewer cervical cancer deaths to the programme, and recorded zero deaths from cervical cancer among women aged 20-24 across 2020-2024. Public Health Scotland reported in 2024 that no cervical cancer cases had yet been detected in women who received full HPV immunisation at age 12-13 since the national programme began in 2008. Australia, an early adopter from 2007, saw a 77% fall in HPV infection among women aged 18-24 within five years and a 50% fall in high-grade cervical lesions in the same age group, and is now modelled to be on track to become one of the first countries to effectively eliminate cervical cancer as a public health problem, around 2035. Every one of these gains, however, accrues only to those vaccinated before infection; none of it helps the very large population already living with HPV16/18-driven neoplasia or established cancer, which is precisely the population this report's target product profiles are built around.

WHO's global cervical cancer elimination strategy, adopted in 2020, sets programmatic 90-70-90 targets for 2030 (90% of girls fully vaccinated by age 15, 70% of women screened with a high-performance test by ages 35 and 45, and 90% of women with cervical disease receiving treatment). As of the most recent published progress reviews, no country has yet reached elimination threshold, and modelling of the 90-70-90 pathway suggests full elimination as a public health problem remains a multi-decade, not a 2030, endeavour for most of the world, even as the 2030 targets themselves are on track to avert an estimated 300,000 deaths. That long runway, alongside the scale of disease already established in patients today, is the enduring commercial rationale for a therapeutic vaccine.

2026 662,301 new cervical cancers/year  |  348,874 deaths/year  |  ~11-12% worldwide HPV prevalence  |  PDS0101 now in Phase 3 (VERSATILE-003)
Product & competitor landscape

From two historic frontrunners to a new field leader

When this report was first published in April 2019, Advaxis's AXAL and Inovio's VGX-3100 were the field's clearest efficacy signals. Both have since been discontinued in their original indications, and PDS Biotech's PDS0101 has emerged as the most clinically advanced HPV therapeutic vaccine candidate worldwide, now in a registrational Phase 3 trial.

  • Advaxis / Ayala PharmaceuticalsAIM2CERV discontinued
    AXAL (axalimogene filolisbac) Lm-LLO listeria-vectored, anti-E7
    The Phase 3 AIM2CERV trial in high-risk locally advanced cervical cancer was discontinued; Advaxis's Lm-LLO immunotherapy platform was deprioritised following the company's 2021 reverse merger into Ayala Pharmaceuticals, which has not continued the programme.
  • Inovio Pharmaceuticals / ApolloBioUS programme discontinued, 2023
    VGX-3100 Synthetic DNA, anti-E6/E7
    Mixed Phase 3 REVEAL1/REVEAL2 results in HPV16/18+ CIN2/3 led Inovio to discontinue US development in August 2023. Under a 2018 licence, China partner ApolloBio's own pivotal Phase 3 trial met its primary efficacy endpoint in 2026 and is now advancing toward a Chinese regulatory submission.
  • PDS BiotechVERSATILE-003 discontinued, Aug 2026
    PDS0101 (Versamune HPV) Lipid-based peptide, anti-E6/E7
    Final Phase 2 VERSATILE-002 data in combination with pembrolizumab reported a median overall survival of 39.3 months in HPV16-positive recurrent/metastatic head and neck cancer (CPS ≥1), against a historical benchmark of around 17.9 months for pembrolizumab alone. On 11 August 2026, PDS Biotech announced a strategic refocus onto its IL-12 immunocytokine PDS0301 in metastatic colorectal cancer, discontinuing further internal investment in the registrational Phase 3 VERSATILE-003 trial and stating it will instead pursue a strategic partnership or other externally funded route to continue PDS0101's development. On 8 September 2026, the company disclosed a PIPE financing of up to $22.55m led by Nant Capital (Dr. Patrick Soon-Shiong, NantWorks), under which NantWorks was granted a one-year exclusive right to negotiate an exclusive licence to PDS0101 - the first concrete step toward the externally funded partnership route flagged in August. On 14 September 2026, PDS Biotech confirmed the initial closing of that financing (an $11.3m gross tranche) and the appointment of Dr. Soon-Shiong and Nant Capital's James Banaag to its board, with a further $11m contingent on a Phase 3 protocol submission for PDS0301 - board-level confirmation that the NantWorks negotiation window over PDS0101 is now active.
  • TransgenePhase 2 missed endpoint, under review
    TG4001 MVA-vectored, anti-E6/E7
    Combined with avelumab in recurrent/metastatic HPV16+ cervical and anogenital cancer, the randomised Phase 2 trial missed its primary progression-free survival endpoint (October 2024), though a pre-planned subgroup analysis suggested a positive trend specifically in cervical cancer patients, now under further review.
  • BioNTechPhase 2, ongoing
    BNT113 mRNA-lipoplex, anti-E6/E7
    An HPV16-targeted mRNA therapeutic combined with pembrolizumab in HPV16-positive head and neck cancer. Early Phase 2 data reported an unconfirmed overall response rate of around 40%, the most advanced mRNA-based approach in the therapeutic HPV field to date.
Field leadership shift
39.3 months

PDS Biotech's PDS0101, not either of the field's historic frontrunners, remains the clinical efficacy benchmark for HPV therapeutic vaccines, but its path to registration has just been thrown into question. Combined with pembrolizumab, it reported a median overall survival of 39.3 months in HPV16-positive recurrent/metastatic head and neck cancer, more than double the historical benchmark for pembrolizumab alone. On 11 August 2026, however, PDS Biotech announced it would discontinue the registrational VERSATILE-003 Phase 3 trial and cease further internal funding of PDS0101, refocusing the company on its PDS0301 immunocytokine and seeking a partner to carry PDS0101 forward instead. Both AXAL and VGX-3100, the two candidates this report tracked at its April 2019 launch, have since been discontinued in their original US indications, though VGX-3100 continues toward a Chinese approval via ApolloBio. The VacZine Analytics model quantifies the commercial opportunity this reshuffled competitive landscape creates across both the neoplasia and established-cancer target product profiles.

Scope of analysis

Six analytical layers - one commercial picture

The MarketVIEW HPV therapeutic analysis spans disease burden, dual target product profile design, the post-2019 competitor landscape and patient-based demand forecasting for major Western markets to 2035.

Western-market patient forecast

Patient-based value/volume demand modelling to 2035 across major Western markets, for both target product profiles.

Competitor & pipeline review

PDS Biotech's PDS0101, Inovio's VGX-3100/ApolloBio, Transgene's TG4001, BioNTech's BNT113, and the discontinued AXAL and US VGX-3100 programmes.

Dual target product profile framing

Separate TPPs for HPV16/18+ neoplasia (CIN/AIN/PIN/VIN/VAIN) and established cancer (cervical, oropharyngeal, anal), reflecting materially different clinical pathways.

Pricing & cost-effectiveness

Pricing considerations and cost-effectiveness discussion appropriate to a therapeutic vaccine positioned alongside checkpoint-inhibitor combination regimens.

Disease burden & epidemiology

Updated global burden data (GLOBOCAN 2022), WHO 90-70-90 elimination-strategy progress, and real-world prophylactic-vaccine impact data from England, Scotland and Australia.

Early decision-making support

Designed as an ideal tool to aid early-stage decision making in HPV therapeutic vaccine development, investment and market entry planning.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the indication and geography framework. Full patient-based volume/value outputs, pricing assumptions and country-level data are in the licensed model.

IndicationGeographyTarget groupVaccine statusRevenue scenario
CIN2/3 (HPV16/18+)US + EU5Neoplasia (pre-cancer)Phase 3 (China)Modelled
Cervical cancer (recurrent/persistent)Major Western marketsEstablished cancerPhase 3Modelled
Oropharyngeal cancer (HPV16+)US + EU5Established cancerPhase 3 (VERSATILE-003)Modelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - baseAll geographiesAll groupsAll scenarios$███m
Full model in the licensed workbook
Major Western markets · to 2035 · both target product profiles
Register interest →
Deliverables

What you receive

A comprehensive intelligence package combining a detailed executive presentation and an optional interactive forecast model, built for organisations evaluating the HPV therapeutic vaccine opportunity across major Western markets.

  • Executive presentation (185 slides) - disease background, global burden, dual target product profile design, clinical development issues and full competitive environment review
  • MS-Excel patient-based value/volume forecast model (optional) - demand outputs to 2035 across both neoplasia and established-cancer indications
  • Major Western market coverage - patient-based modelling built up from disease-stage populations, not top-down assumptions
  • Competitor intelligence - PDS Biotech's PDS0101, Inovio's VGX-3100/ApolloBio, Transgene's TG4001, BioNTech's BNT113, and the discontinued AXAL and US VGX-3100 programmes
  • Updated epidemiology module - GLOBOCAN 2022 global burden data, WHO 90-70-90 elimination-strategy progress, and real-world prophylactic-vaccine impact data from England, Scotland and Australia
  • Early decision-making support - ideal target product profile and market entrance strategy guidance for early-stage HPV therapeutic vaccine planning
Target audience

Built for organisations evaluating the HPV therapeutic vaccine opportunity

Most valuable to teams assessing the HPV therapeutic vaccine market against their own pipeline, BD ambitions or investment thesis, now that the field's competitive leadership has changed hands.

Vaccine developers

Positioning, target product profile and commercial feasibility assessment for HPV therapeutic candidates at any stage.

Corporate strategy & BD

Validate the size and structure of a market that has just changed leaders, now that PDS0101 has proven a registrational efficacy signal is achievable.

Investors & analysts

Independent assessment of pipeline risk and commercial upside for due diligence on PDS Biotech and the wider HPV therapeutic vaccine field.

Public health & immunisation programmes

Context on how far prophylactic HPV vaccination and screening have progressed against WHO's 90-70-90 targets, and where a therapeutic option still fills the gap.

Researchers & academia

Comprehensive epidemiology and R&D landscape for grant, translational and target product profile planning.

Market access & policy

Pricing benchmarks and access-pathway assumptions for a therapeutic vaccine likely to be positioned alongside existing oncology standards of care.

About this analysis · VAMV050

VacZine Analytics has long standing expertise in Adolescent and STD diseases, positioning us to track the HPV therapeutic vaccine opportunity from its earliest clinical signals through to today's substantially reshuffled competitive field. This is a genuinely comprehensive analysis with a patient-based methodology, distinguishing carefully between the neoplasia and established-cancer target populations, and it has been well received by clients across the field for the depth of its target product profile and clinical development review. Few groups have followed this market as closely across such a long horizon, and that recognised, independent expertise underpins everything in the analysis.

This report was last published in April 2019; any refresh would incorporate current global burden data, WHO elimination-strategy progress, real-world prophylactic-vaccine impact evidence, and the substantial reshuffling of the competitive landscape, including the discontinuation of both AXAL and the US VGX-3100 programme and the emergence of PDS Biotech's PDS0101 as field leader. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV050 · Syndicated & bespoke

Syndicate the refresh - or commission the answer you need

Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc HPV therapeutic vaccine analysis, a briefing call is included on request.